You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 141 No. 3, March 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Observation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (14)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Hematology/ Hematologic Malignancies
 •Leukemias/ Lymphomas
 •Dermatologic Disorders, Other
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic

Imatinib-Induced Sweet Syndrome in a Patient With Chronic Myeloid Leukemia

Sanjay J. Ayirookuzhi, MD; Li Ma, MD; Priya Ramshesh, MD; Glenn Mills, MD

Arch Dermatol. 2005;141:368.

Background  Imatinib mesylate has become one of the main chemotherapeutic agents currently used to treat patients with chronic myeloid leukemia (CML). Although cutaneous reactions to this drug have been documented before, this is the first time that Sweet syndrome has been reported with its use.

Observations  We report a case of Sweet syndrome secondary to the administration of imatinib to treat CML. On 2 separate occasions, a 53-year-old African American woman with CML developed neutrophilic dermatosis consistent with Sweet syndrome after chemotherapy with imatinib.

Conclusion  Greater awareness of the adverse effects of imatinib and the characterization of its cutaneous adverse effects will lead to improved surveillance for and treatment of those adverse effects.


Author Affiliations: Departments of Medicine (Dr Ayirookuzhi), Pathology (Dr Ma), and Hematology and Oncology (Drs Ramshesh and Mills), Louisiana State University Health Sciences Center at Shreveport, Shreveport.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Bullous Sweet Syndrome in a Patient With t(9;22)(q34;q11)-Positive Chronic Myeloid Leukemia Treated With the Tyrosine Kinase Inhibitor Nilotinib: Interphase Cytogenetic Detection of BCR-ABL- Positive Lesional Cells
Kaune et al.
Arch Dermatol 2008;144:361-364.
ABSTRACT | FULL TEXT  

Drug-Induced Sweet's Syndrome
Thompson and Montarella
The Annals of Pharmacotherapy 2007;41:802-811.
ABSTRACT | FULL TEXT  

Newly Reported Associations with Neutrophilic Dermatoses
Journal Watch Dermatology 2005;2005:6-6.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.